Scarica l'app Stockscreener
32.87
0.67%
0.22
Pre-mercato:
33.37
0.50
+1.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Top 3 Health Care Stocks That Could Blast Off This Quarter - Benzinga
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025? - The Motley Fool
What’s next for hot biotech stock Viking Therapeutics? Here’s how the company can scale up. - MSN
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert - 24/7 Wall St.
Here’s how hot biotech stock Viking Therapeutics can scale up - MarketWatch
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data - MSN
Royal Fund Management LLC Raises Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics: The Turning Point Is Not Here Yet - Seeking Alpha
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Zacks Investment Research
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week - MSN
These 10 Firms Were Last Week’s Worst Performers - Insider Monkey
Viking Therapeutics (NASDAQ:VKTX) Shares Down 4.8%Here's Why - MarketBeat
Shelton Wealth Management LLC Purchases New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Viking Therapeutics (NASDAQ:VKTX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today - sharewise
Viking Therapeutics (NASDAQ:VKTX) Trading Down 4.8%Here's What Happened - MarketBeat
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - AOL
Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential - MSN
We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks - MSN
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down - Yahoo Finance
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy. - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc.VKTX - PR Newswire
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday - MSN
Viking Therapeutics Becomes Oversold (VKTX) - Nasdaq
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Viking Therapeutics’ oral-2735 could differentiate asset, says JPMorgan - MSN
International Assets Investment Management LLC Reduces Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics begins VK2735 Phase II trial for obesity treatment - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Viking Therapeutics begins phase 2 trial for obesity drug By Investing.com - Investing.com Nigeria
Should You Buy the Dip on This High-Flying Stock? - AOL
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - The Malaysian Reserve
Viking Therapeutics (NASDAQ:VKTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral - GuruFocus.com
Viking Therapeutics begins phase 2 trial for obesity drug - Investing.com
Viking Therapeutics Launches Phase 2 Trial for Oral Weight Loss Drug After Impressive Early Results - StockTitan
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Viking Therapeutics COO sells $2.3 million in stock By Investing.com - Investing.com South Africa
Viking therapeutics CEO sells $8.3 million in stock - Investing.com India
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 50,309 Shares of Stock - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells 54,215 Shares of Stock - MarketBeat
Viking therapeutics CEO sells $8.3 million in stock By Investing.com - Investing.com Nigeria
Viking Therapeutics CFO sells shares worth $2.15 million By Investing.com - Investing.com Nigeria
Viking Therapeutics COO sells $2.3 million in stock - Investing.com
VKTXViking Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
President & CEO Lian Brian was granted 256,133 shares and sold $8,313,601 worth of shares (194,490 units at $42.75), increasing direct ownership by 3% to 2,366,570 units (SEC Form 4) - Quantisnow
Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4) - Quantisnow
Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4) - Quantisnow
SEC Form 4 filed by Director Macartney Lawson - Quantisnow
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):